Weekly Spotlight - 09.01.25

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

New Treatment Leads to Motor Function Gains in SMA Type 2 Patients

Researchers have found that administering the gene therapy Zolgensma directly into the spinal canal can lead to significant motor function improvements in patients with spinal muscular atrophy type 2. This method shows promise as a more effective delivery route compared to traditional intravenous administration.

Gene Therapy Shows Promise in Slowing Progression of SMA in Children

A new gene therapy has shown promising results in slowing the progression of spinal muscular atrophy type 2. The treatment involves replacing a faulty gene responsible for the condition, leading to improved muscle function and overall health in patients. This breakthrough offers hope for managing the disease more effectively.

Novartis' Zolgensma Offers Hope for Older SMA Patients After FDA Delay

Novartis has announced positive results from a pivotal trial of intrathecal Zolgensma, a gene therapy, in older patients with spinal muscular atrophy. The trial showed significant improvements in motor function, marking a potential treatment advancement for this patient group. The FDA had previously delayed the trial due to safety concerns.

Boosting SMN Protein Levels Enhances SMA Treatment Outcomes in Patients

Researchers are exploring ways to increase SMN protein levels to enhance the effectiveness of therapies for spinal muscular atrophy. Higher SMN protein levels can improve muscle function and overall health in individuals with SMA, making current treatments more potent and beneficial.